葵花药业(002737.SZ)及相关人员收到黑龙江证监局警示函

Core Viewpoint - The company received a warning letter from the Heilongjiang Securities Regulatory Bureau for failing to comply with related party transaction disclosure regulations, involving a transaction amount of 32.38 million yuan, which is 0.68% of the company's latest audited net assets [1][2]. Group 1: Regulatory Actions - The Heilongjiang Securities Regulatory Bureau issued a warning letter to the company and its executives, including the chairman and general manager, for not following the required procedures for related party transactions and information disclosure [2]. - The warning letter will be recorded in the securities and futures market integrity archives [2]. Group 2: Related Party Transactions - The company engaged in a procurement transaction with Shanghai Haiwei Biotechnology Co., a wholly-owned subsidiary of its related party, Geluori (Wuxi) Nutrition Technology Co., with a transaction amount of 32.38 million yuan [1]. - The company did not fulfill the necessary review procedures and disclosure obligations for this related party transaction, violating multiple provisions of the Information Disclosure Management Measures for Listed Companies [1].